Michigan Early Disease Progression Cohort

COPD Clinical Trial

— MAP_COPD  

Official title:

Michigan eArly Disease Progression Cohort in COPD (MAP COPD)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04968249
• Other study ID #: HUM00176147
• Status: Active, not recruiting
• Start date: July 30, 2021
• Est. completion date: July 2024

Study information

• Verified date: April 2024
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this project is to develop a disease progression cohort within the University of Michigan Health System to capture pulmonary function, symptom assessments and quantitative imaging among patients at risk for or with an established diagnosis of COPD, focusing however on "early" COPD (age 30-55 and GOLD stage 0,1, 2, and prism).

Description:

Participants between the ages of 30-55 with at least 10 pack-year smoking history will be enrolled into a observational longitudinal cohort.

During the course of the study, additional funding was secured, so data could be collected for a 3-year period from participants. Some of the cohort are co-enrolled in another study (NCT05033990) where they received a CT scan as part of the study. Those participants will not be re-scanned during the course of this study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 55 Years

Eligibility

Inclusion Criteria:

• GOLD 0 Participant must be ages 30-55 years; and have: = 10 pack-year smoking history; post-bronchodilator FEV1/FVC = 0.70 and FEV1 = 80% predicted.

• Preserved Ratio Impaired Spirometry (PRISm) participants shall be between ages 30-55 years; and have: = 10 pack-year smoking history; post-bronchodilator FEV150-79% predicted and FEV1/FVC > 0.70.

• GOLD 1 participants shall be between ages 30-55 years, and have: = 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 >= 80% predicted. OR

• GOLD 2 participants shall be between ages 30-55 years, and have: = 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 50-79% predicted.

Exclusion Criteria:

• Severe asthma, which is defined as any of the following:

Current (i.e., at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = >250 fluticasone propionate =100 fluticasone furoate, >200 beclomethasone, >400 budesonide, >220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS.

or 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months or One asthma hospitalization in the past 12 months

• Concurrent participation in a therapeutic trial where treatment is blinded.

• Active pregnancy at the time of the baseline or return visits. This special population is being excluded to minimize potential for fetal radiation exposure.

• Cognitive dysfunction that prevents the participant from completing study procedures.

• BMI > 35.0 kg/m2 at baseline, due to the effects of body weight on CT scan imaging quality.

• The presence of a respiratory condition other than COPD or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g., dyspnea or decreased exercise tolerance).

• Any illness expected to cause mortality in the next 3 years.

• Any implanted metallic devices or prosthesis above the waist that could degrade thoracic CT scan image quality.

• History of thoracic radiation or thoracic surgery with resection of lung tissue

Related Conditions & MeSH terms

• COPD
• Disease Progression

Intervention

Other:
• Observational
Observational Cohort to understand risk factors for early COPD.

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

References & Publications (1)

Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, Celli BR, Christenson SA, Crystal RG, Fageras M, Freeman CM, Groenke L, Hoffman EA, Kesimer M, Kostikas K, Paine R 3rd, Rafii S, Rennard SI, Segal LN, Shaykhiev R, Stevenson C, Tal-Singer R, Vestbo J, Woodruff PG, Curtis JL, Wedzicha JA. At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551. doi: 10.1164/rccm.201710-2028PP. No abstract available. Erratum In: Am J Respir Crit Care Med. 2018 Dec 1;198(11):1463. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CAAT score = 10	Proportion of individuals with CAAT score = 10	3 years
Primary	Exacerbations in the prior year	Frequency of moderate and severe exacerbations in the prior year measured at baseline	3 years
Secondary	Radiographic abnormalities on baseline CT	Proportion of individuals with radiographic abnormality on baseline CT defined as PRMfSAD=15% and/or PRMEmph =3%	3 years